SEHK:9966Biotechs
Assessing Alphamab Oncology’s Valuation After JSKN033 Phase II Trial Progress In Advanced Cervical Cancer
Alphamab Oncology (SEHK:9966) has dosed the first patient in its phase II trial of JSKN033, a high concentration subcutaneous HER2 bispecific ADC and PD-L1 therapy combined with platinum-based chemotherapy for advanced cervical cancer.
See our latest analysis for Alphamab Oncology.
The JSKN033 update comes as momentum around Alphamab Oncology's HK$9.35 share price has picked up in the very near term, with a 1-day share price return of 6.25% and 7-day share price return of 10.91%, following a...